Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE 4 trilaciclib vs placebo in metastatic NSCLC treated with docetaxel (2nd/3rd line)
2021-000186-32Phase 2Terminated
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing trilaciclib + docetaxel with placebo + docetaxel (2 arms). Primary endpoint: Overall survival. Started Jun 2021; status: terminated.
02
Drugs
trilaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-000186-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000186-32.